Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
A legfontosabb adatok
- Hol
- Atlanta (Egyesült Államok)Mind a 2 helyszín megnézése
- Fázis
- 2. fázis
Neked szólhat?
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 1 és 75 év között vagy?
Forrás: NCT02828592: ki vehet részt
Helyszínek itt: Egyesült Államok
- Blood and Marrow Transplant Group of GeorgiaAtlanta, Egyesült ÁllamokContact: Melhem Solh, MDRésztvevőt keres
- Northside HospitalAtlanta, Egyesült ÁllamokContact: Melhem Solh, MDRésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Northside Hospital, Inc.
- Azonosító
- NCT02828592
- A regiszteradat frissítve
- 2026. október 14.
- Eredeti leírás
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.A teljes eredeti leírásKevesebb
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an immune-mediated mechanism that results in severe pancytopenia and high risk for infections and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance of survival; however, a response rate with just immunosuppression for those patients lacking suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3 relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical donor for transplantation has good response rates and significantly lower rates of acute and chronic GVHD.
Bevonási feltételek: Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have negative HLA cross-match in the host vs. graft direction; Age <= 65 years for previously treated and <= 75 years for previously treated patients; KPS >= 70%; Aplastic Anemia that meets the following criteria:; Peripheral Blood (must fulfill 2 of 3):; <500 PMN/mm3; <20,000 platelets; absolute reticulocyte count <40,000/microL; Bone Marrow (must be either):; markedly hypocellular (<25% of normal cellularity); moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral blood criteria above.
Kizáró feltételek: prior allogeneic transplant; poor cardiac function (LVEF <40%); poor renal function (creatinine >= 2.0mg/dL or creatinine clearance <40mL/min); poor pulmonary function (FEV1 \& FVC <50% predicted); poor liver function (bili >= 2mg/dL).